Xenazine is the first and only FDA-approved treatment specifically developed for any Huntington’s disease-related symptom, the company said.
Paul Dreyer, president of S&R, said: “In recent months, the S&R team worked tirelessly to help Ovation launch Xenazine. Having been involved since 2005 in marketing efforts for Xenazine, we know that it is a major advance for those with Huntington’s disease. We are pleased to help Ovation bring this important product to patients, physicians and caregivers.”